BioNTech Secures CureVac Acquisition in Landmark mRNA Deal

The German biotechnology firm BioNTech is on the verge of a significant strategic achievement, having successfully navigated the primary hurdle for its proposed acquisition of rival CureVac. An overwhelming majority of CureVac shareholders have given their approval, paving the way for BioNTech to integrate a promising portfolio of mRNA technologies and product candidates. Despite this positive development, the market’s initial reaction has been muted, raising questions about whether investors are overlooking the long-term potential of this consolidated entity.

Institutional Confidence and Analyst Optimism

A strong signal of confidence has emerged from the institutional investment community. Franklin Resources, a major US asset manager, substantially increased its stake in BioNTech by 76.8 percent. This move brings its total holding to 751,998 shares, valued at approximately $80.1 million. Such significant accumulation by a sophisticated investor is often interpreted as a vote of confidence in the company’s fundamental prospects, particularly during periods of short-term market uncertainty. It appears that professional investors are using the current phase of consolidation to position themselves ahead of the finalization of the CureVac transaction and its potential pipeline benefits.

Market analysts are also expressing considerable optimism. The investment bank Berenberg reaffirmed its “Buy” rating on November 27, attaching a price target of $150 USD. This projection implies a potential upside of over 70 percent from the stock’s recent levels, a stark contrast to the market’s tepid response that same day, which saw shares decline by about 2.25 percent to 87 euros. The consensus among analysts, with an average price target of $135.20, also sits significantly above the current trading price, suggesting a widespread belief in the long-term value of the expanded product pipeline rather than a focus on near-term quarterly results.

Should investors sell immediately? Or is it worth buying BioNTech?

Shareholder Overwhelmingly Approve Merger Terms

The path for the acquisition was cleared during CureVac’s extraordinary general meeting held on November 25, 2025. The shareholder vote was nearly unanimous, with more than 99.16 percent of the cast votes supporting the takeover proposal from BioNTech.

The exchange offer for CureVac shareholders remains open until 3:00 PM German time on December 3, 2025. Under the terms, CureVac stockholders will receive 0.05363 BioNTech American Depositary Shares (ADRs) for each of their shares. This exchange ratio is based on a volume-weighted average price of $101.88 per BioNTech share. The deal includes a notable incentive for shareholders to act promptly: those who do not tender their shares by the deadline could subsequently face a 15 percent Dutch withholding tax on dividends.